BridgeBio Pharma (NASDAQ: BBIO) made its public debut Thursday morning, opening at $30.61 after being priced at $17 per share.
JPMorgan, Goldman Sachs, Jefferies, SVB Leerink, KKR, Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James are the underwriters for the offering.
BridgeBio Pharma was founded in 2015 and headquartered in Palo Alto, California. The company focuses on identifying and advancing transformative medicines to treat diseases that arise from defects in a single gene, and for cancers with clear genetic drivers.
Its pipeline consists of over 15 development programs that are evaluating product candidates in early discovery to late-stage development.
The stock traded around $30 per share at time of publication.
BridgeBio Pharma IPO: What You Need To Know
Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA
See more from Benzinga
- Report: Howard Hughes Exploring Strategic Alternatives, Possible Sale
- ImmunoGen To Focus Operations On Mivetuximab Soravtansine Development
- Seelos Therapeutics Shares Rally Following Deal For Gene Therapy Program
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.